Cytokinetics Inc (CYTK) FinancialsCYTKFinancialCytokinetics Inc

Evaluating the bottom line, Cytokinetics, Incorporated maintains a gross margin of 80.46%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -625.95%, while the net margin is -694.39%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CYTK converts its operational activities into shareholder value.

In the context of the broader market, CYTK competes directly with industry leaders such as RGEN and IONS. With a market capitalization of $10.31B, it holds a leading position in the sector. When comparing efficiency, CYTK's gross margin of 80.46% stands against RGEN's 53.91% and IONS's 98.98%. Such benchmarking helps identify whether Cytokinetics, Incorporated is trading at a premium or discount relative to its financial performance.

Cytokinetics has shown a gross margin of 80.46% in Q2 2026, but it continues to report negative net income, with a net loss of $198,762,000 in the same quarter. The forward P/E ratio is extremely high at 117.6471, indicating potential overvaluation.